Floatz logo

Mifepristone

Invasive Breast Cancer

University of California, San DiegoSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

59 Active assets in the Invasive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
University of California, San Francisco
Phase 4BBB
Letrozole
Emory University
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
Arimidex
Jonsson Comprehensive Cancer Center
Phase 4BBB
Carboplatin
Baylor Breast Care Center
Phase 3BB

View all 50 →

Same molecule, other indications

Mifepristone is also rated in:

psychotic disorderDormant
BB
Indicative ·
64 / 100
View asset →
major depressive disorderDormant
B
Indicative ·
63 / 100
View asset →
Cushing syndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →